Weekly Digests



Interferon-III interferes with breast cancer

April 29, 2020

Dendritic cells play a critical role in kickstarting immune responses, and cDC1s, which cross-present antigens and activate CD8+ T cells, are of particular interest for inducing responses to immunotherapy. Previous research has shown tumor infiltration by cDC1s to be associated with favorable patient prognoses and improved clinical responses to anti-PD-1. In a paper...

Just a few neoantigens may be enough for T cells to control prostate cancer

April 22, 2020

Can checkpoint blockade benefit patients whose cancers have low tumor mutational burden? To address this question, Subudhi et al. conducted a phase II clinical trial of patients with advanced prostate cancer – a cancer known to have a relatively low mutational load – who were treated with ipilimumab, and evaluated their treatment-induced immune...

It’s best to be selective – targeting TGFβ1

April 15, 2020

TGFβ is known to play a role in immunosuppression and resistance to immune checkpoint blockade, however, efforts to block TGFβ to enhance immunotherapy have been limited by cardiotoxicity. TGFβ exists in three isoforms – TGFβ1, TGFβ2, and TGFβ3 – and while TGFβ2 and TGFβ3 have been linked to cardiac function, TGFβ1 has not...

Vaccine + chemo activate immune response against cervical cancer

April 8, 2020

While a therapeutic human papilloma virus type 16 (HPV16) vaccine can effectively promote an immune response and subsequent durable regressions of HPV16-induced premalignant lesions, it has shown no clinical benefit in patients with late-stage HPV16-induced cervical cancer. To address the immunosuppressive environment that prevents the vaccine from inducing a strong immune response in...

Release the B7.1! Anti-PD-L1 breaks PD-L1’s grip

April 1, 2020

Blocking the PD-1/PD-L1 axis using anti-PD-L1 antibodies is a commonly employed immunotherapeutic strategy to prevent PD-1-mediated inhibition of T cells by tumor cells. Suspecting that the mechanism of action of PD-L1 blockade might be more complex, however, Mayoux et al. investigated the role of PD-L1-expressing dendritic cells (DCs) in PD-L1 blockade. The results...

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.